Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours

por Zhang, Jian, Liu, Rujiao, Gao, Shuiping, Li, Wenhua, Chen, Yang, Meng, Yanchun, Liu, Chang, Jin, Wenyue, Wu, Junyan, Wang, Ying, Hao, Yanrong, Yi, Shuli, Qing, Yan, Ge, Junyou, Hu, Xichun
Publicado 2023

Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study

por Shi, Yuankai, Qin, Xintian, Peng, Xingchen, Zeng, Aiping, Li, Jingao, Chen, Chuanben, Qiu, Sufang, Pan, Suming, Zheng, Yulong, Cai, Jing, Chen, Xiaopin, Qu, Shenhong, Lin, Lizhu, Huang, Jianli, Wu, Hui, Lu, Ying, Wang, Wei, Hu, Changlu, He, Xia, Yu, Zhonghua, Liu, Xiaojian, Xie, Bo, Liu, Anwen, Hu, Guangyuan, Jing, Shanghua, Zhang, Qingyuan, Guo, Renhua, Li, Qi, Hong, Jinsheng, Jin, Feng, Meng, Juan, Shi, Jianhua, Wang, Peiguo, Cui, Jiuwei, Yang, Kunyu, Zhang, Xuebang, Li, Xiaojiang, Shen, Liangfang, He, Yuxiang, Zhai, Limin, Sun, Xiuhua, Ge, Junyou, Qing, Yan, Zong, Dekang
Publicado 2022